

RESEARCH ARTICLE

Predictive validity of the quick Sequential Organ Failure Assessment (qSOFA) score for the mortality in patients with sepsis in Vietnamese intensive care units

Son Ngoc Do^{1,2,3}, Chinh Quoc Luong^{2,3,4}*, My Ha Nguyen⁵, Dung Thi Pham⁶, Nga Thi Nguyen⁷, Dai Quang Huynh^{8,9}, Quoc Trong Ai Hoang¹⁰, Co Xuan Dao^{1,2,3}, Thang Dinh Vu¹¹, Ha Nhat Bui¹², Hung Tan Nguyen¹³, Hai Bui Hoang^{2,14}, Thuy Thi Phuong Le¹⁵, Lien Thi Bao Nguyen¹⁶, Phuoc Thien Duong¹⁷, Tuan Dang Nguyen¹⁸, Vuong Hung Le¹⁹, Giang Thi Tra Pham²⁰, Tam Van Bui⁷, Giang Thi Huong Bui^{1,2}, Jason Phua^{21,22}, Andrew Li²², Thao Thi Ngoc Pham^{8,9}, Chi Van Nguyen^{2,4}, Anh Dat Nguyen^{2,4}



OPEN ACCESS

Citation: Do SN, Luong CQ, Nguyen MH, Pham DT, Nguyen NT, Huynh DQ, et al. (2022) Predictive validity of the quick Sequential Organ Failure Assessment (qSOFA) score for the mortality in patients with sepsis in Vietnamese intensive care units. PLoS ONE 17(10): e0275739. <https://doi.org/10.1371/journal.pone.0275739>

Editor: Dinh-Toi Chu, International School, Vietnam National University, VIET NAM

Received: December 27, 2021

Accepted: September 22, 2022

Published: October 14, 2022

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0275739>

Copyright: © 2022 Do et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its [Supporting Information](#) files.

1 Center for Critical Care Medicine, Bach Mai Hospital, Hanoi, Vietnam, **2** Department of Emergency and Critical Care Medicine, Hanoi Medical University, Hanoi, Vietnam, **3** Faculty of Medicine, University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam, **4** Center for Emergency Medicine, Bach Mai Hospital, Hanoi, Vietnam, **5** Department of Health Organization and Management, Faculty of Public Health, Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam, **6** Department of Nutrition and Food Safety, Faculty of Public Health, Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam, **7** Department of Intensive Care and Poison Control, Vietnam-Czechoslovakia Friendship Hospital, Hai Phong, Vietnam, **8** Intensive Care Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam, **9** Department of Critical Care, Emergency Medicine and Clinical Toxicology, Faculty of Medicine, Ho Chi Minh City University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam, **10** Emergency Department, Hue Central General Hospital, Hue City, Thua Thien Hue, Vietnam, **11** Intensive Care Unit, People's Hospital 115, Ho Chi Minh City, Vietnam, **12** Intensive Care Unit, Bai Chay General Hospital, Quang Ninh, Vietnam, **13** Intensive Care Unit, Da Nang Hospital, Da Nang City, Vietnam, **14** Emergency and Critical Care Department, Hanoi Medical University Hospital, Hanoi Medical University, Hanoi, Vietnam, **15** Intensive Care Unit, Dong Da General Hospital, Hanoi, Vietnam, **16** Intensive Care Unit, Saint Paul General Hospital, Hanoi, Vietnam, **17** Intensive Care Unit, Can Tho Central General Hospital, Can Tho, Vietnam, **18** Intensive Care Unit, Vinmec Times City International Hospital, Hanoi, Vietnam, **19** Intensive Care Unit, Thai Nguyen National Hospital, Thai Nguyen, Vietnam, **20** Emergency Department, Thanh Nhan General Hospital, Hanoi, Vietnam, **21** FAST and Chronic Programmes, Alexandra Hospital, National University Health System, Singapore, **22** Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Health System, Singapore, Singapore

* These authors contributed equally to this work.

* luongquocchinh@gmail.com

Abstract

Background

The simple scoring systems for predicting the outcome of sepsis in intensive care units (ICUs) are few, especially for limited-resource settings. Therefore, this study aimed to evaluate the accuracy of the quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) score in predicting the mortality of ICU patients with sepsis in Vietnam.

Methods

We did a multicenter cross-sectional study of patients with sepsis (≥ 18 years old) presenting to 15 adult ICUs throughout Vietnam on the specified days (i.e., 9th January, 3rd April,

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

3rd July, and 9th October) representing the different seasons of 2019. The primary and secondary outcomes were the hospital and ICU all-cause mortalities, respectively. The area under the receiver operating characteristic curve (AUROC) was calculated to determine the discriminatory ability of the qSOFA score for deaths in the hospital and ICU. The cut-off value of the qSOFA scores was determined by the receiver operating characteristic curve analysis. Upon ICU admission, factors associated with the hospital and ICU mortalities were assessed in univariable and multivariable logistic models.

Results

Of 252 patients, 40.1% died in the hospital, and 33.3% died in the ICU. The qSOFA score had a poor discriminatory ability for both the hospital (AUROC: 0.610 [95% CI: 0.538 to 0.681]; cut-off value: ≥ 2.5 ; sensitivity: 34.7%; specificity: 84.1%; $P_{\text{AUROC}} = 0.003$) and ICU (AUROC: 0.619 [95% CI: 0.544 to 0.694]; cutoff value: ≥ 2.5 ; sensitivity: 36.9%; specificity: 83.3%; $P_{\text{AUROC}} = 0.002$) mortalities. However, multivariable logistic regression analyses show that the qSOFA score of 3 was independently associated with the increased risk of deaths in both the hospital (adjusted odds ratio, AOR: 3.358; 95% confidence interval, CI: 1.756 to 6.422) and the ICU (AOR: 3.060; 95% CI: 1.651 to 5.671).

Conclusion

In our study, despite having a poor discriminatory value, the qSOFA score seems worthwhile in predicting mortality in ICU patients with sepsis in limited-resource settings.

Clinical trial registration

Clinical trials registry—India: [CTRI/2019/01/016898](https://ctri.nic.in/Clinicaltrials/showbrief.aspx?ctriid=201901016898)

Introduction

Sepsis is defined as life-threatening acute organ dysfunction caused by a dysregulated host response to infection [1]. It contributes to as much as 20.0% of all deaths worldwide [2], and mortality rates remain high at 30.0–45.0% [2–4]. In Asia, the overall hospital mortality of sepsis in the intensive care unit (ICU) fell from 44.5% (572/1285) to 36.6% (1822/4980) over the past ten years [5, 6]; however, it is persistently high in lower-middle-income countries (LMICs), such as Indonesia (68.3%; 41/60) [7], Thailand (42.0%; 263/627) [8], and Vietnam (61.0%; 75/123) [9]. No reference standard exists that enables quick, precise diagnosis and prognosis of sepsis [1, 10]. In 2016, the Sepsis-3 Task Force suggested that an increase of 2 points in the Sequential (Sepsis-Related) Organ Failure Assessment (SOFA) score for patients with a suspected infection could be used as clinical criteria for sepsis [1]. This strategy was supported by content validity (SOFA reflects the facets of organ dysfunction) and predictive validity (the proposed criteria predict downstream events associated with the condition of interest) [11]. However, because many SOFA variables are not routinely measured or are not available, the utility of SOFA is constrained both inside and outside the ICU in settings with limited resources.

The Sepsis-3 Task Force also noted that the quick SOFA (qSOFA) score, a combination of respiratory rate, mental state, and systolic blood pressure, had strong predictive validity for

sepsis in patients outside the ICU [11]. Since then, it has been prospectively investigated in a number of settings, including the emergency department (ED), normal ward, and ICU. However, the results are conflicting as to whether it can reliably identify these populations or predict their risk of dying [12–16]. Because the qSOFA score only requires a clinical examination, it may be especially useful in settings with limited resources. The applicability of this score to various infection types, hospital departments (ED, ward, ICU), and nations is still up for debate.

With 96.462 million inhabitants, Vietnam is an LMIC, 15th in the world and third in Southeast Asia in terms of population [17]. Southeast Asia's hotspot for newly emerging infectious diseases, such as SARS-CoV [18], A(H5N1) avian influenza [19, 20], and ongoing COVID-19 outbreaks worldwide [21], is Vietnam. Other significant causes of sepsis in ICUs across Vietnam include severe dengue [22], *Streptococcus suis* infection [23], malaria [24], and increased antibiotic resistance [25, 26]. Vietnam continues to struggle to provide sufficient resources or adequate diagnostic, prognostic, and treatment approaches for patients with sepsis [27, 28], despite its recent economic growth spurt [29]. Additionally, central hospitals in Vietnam's healthcare system are in charge of receiving patients who need assistance receiving care in local hospital settings [30]. Consequently, the diagnosis, prognosis, and initiation of treatment for patients with sepsis are often delayed.

In resource-limited settings, the early identification of infected patients who may go on to develop sepsis or may be at risk of death from sepsis using simple scoring systems as a way to make a better decision on the treatment of these patients. The aim of this study, therefore, was to evaluate the accuracy of qSOFA score in predicting the mortality of ICU patients with sepsis in Vietnam.

Methods

Study design and setting

This multicenter observational, cross-sectional, point prevalence study is part of the Management of Severe sepsis in Asia's Intensive Care unitS (MOSAICS) II study [6, 31, 32], which enrolled patients on 9th January (Winter), 3rd April (Spring), 3rd July (Summer), and 9th October (Autumn) of 2019. In this study, we used only data from Vietnam. A total of 15 adult ICUs (excluding predominantly neurosurgical, coronary, and cardiothoracic ICUs) participating in the MOSAICS II study from 14 hospitals, of which 5 are central and 9 are provincial, district, or private hospitals, throughout Vietnam. Each ICU had one or two representatives who were part of the local study team and the MOSAICS II study group, as shown in eAppendix 2 of a previously published paper [6]. Participation was voluntary and unfunded.

Participants

All patients admitted to participating ICUs on one of the four days (i.e., January 9th, April 3rd, July 3rd, and October 9th, 2019) which represented the different seasons of 2019 were screened for eligibility. We included all patients, aged ≥ 18 years old, who were admitted to the ICUs for sepsis, and who were still in the ICUs from 00:00 hour to 23:59 hour of the study days. We defined sepsis as infection with a Sequential Organ Failure Assessment (SOFA) score ≥ 2 from baseline (assumed to be 0 for patients without prior organ dysfunction) [1].

Data collection

We used a standardized classification and case record form (CRF) to collect data on common variables as shown in [S1 File](#). The data dictionary of the MOSAICS II study is available as an online supplement of previously published papers [6, 32]. Data was entered by the representatives

of the participating hospitals into the database of the MOSAICS II study via the password-protected online CRFs. We checked the data for implausible outliers and missing fields and contacted ICU representatives for clarification. We then merged the data sets for the 14 hospitals.

Variables

We included variables based on the CRF which is available as shown in [S1 File](#), such as information on: participating hospitals (e.g., central hospital), demographics (e.g., sex, age), comorbidities (e.g., cardiovascular disease, chronic lung disease, chronic neurological disease, chronic kidney disease, peptic ulcer disease, chronic liver disease, diabetes mellitus, and solid malignant tumors), sites of infection (e.g., respiratory, urinary tract, abdominal, neurological, and skin or cutaneous sites), and vital signs (e.g., Glasgow coma score [GCS], heart rate [HR], body temperature, respiratory rate [RR], and blood pressure [BP]) and severity of illness upon ICU admission (e.g., SOFA score, qSOFA score, and septic shock). The qSOFA score ranges from 0 to 3, with one point allocated for each of the following clinical signs: systolic BP ≤ 100 mmHg, RR ≥ 22 breaths/min, and altered mental status from baseline (assumed to be normal for patients with a GCS of 15) [11]. Septic shock was defined as a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain mean arterial pressure ≥ 65 mmHg and having a serum lactate level > 2 mmol/L (18mg/dL) despite adequate volume resuscitation [1]. We also collected information on life-sustaining treatments provided during the ICU stay, e.g., mechanical ventilation (MV) and renal replacement therapy (RRT). We followed all patients till hospital discharge, death in the ICU/hospital, or up to 90 day post-enrollment, whichever was earliest.

Outcomes

The primary outcome was hospital all-cause mortality (hospital mortality). We also examined the following secondary outcomes: ICU all-cause mortality (ICU mortality), and ICU and hospital lengths of stay (LOS).

Sample size

In this cross-sectional study, the primary outcome was hospital mortality. Therefore, based on the hospital mortality rate (61.0%) of our cohort reported in a previously published study [9], we used the formula to find the minimum sample size for estimating a population proportion, with a confidence level of 95% and a confidence interval (margin of error) of $\pm 6.03\%$, and an assumed population proportion of 61.0%. As a result, our sample size should be at least 252 patients. Therefore, our sample size was large enough which reflects a normal distribution.

$$n = \frac{z^2 x \hat{p}(1 - \hat{p})}{\epsilon^2}$$

where:

z is the z score (z score for a 95% confidence level is 1.96)

ϵ is the margin of error (ϵ for a confidence interval of $\pm 6.03\%$ is 0.0603)

\hat{p} is the population proportion (\hat{p} for a population proportion of 61.0% is 0.61)

n is the sample size

Statistical analyses

We used IBM[®] SPSS[®] Statistics 22.0 (IBM Corp., Armonk, United States of America) for data analysis. We report data as numbers and percentages for categorical variables and medians and quartiles (Q1-Q3) in the case of non-normal distribution or means and standard

deviations (SDs) in the case of normal distribution for continuous variables. Comparisons were made between survival and death in the hospital for each variable, using the Chi-squared test or Fisher exact test for categorical variables and the Mann-Whitney U test, Kruskal-Wallis test, one-way analysis of variance for continuous variables.

Receiver operator characteristic (ROC) curves were plotted and the areas under the receiver operating characteristic curve (AUROC) were calculated to determine the discriminatory ability of the qSOFA score for deaths in the hospital and ICU. Additionally, to evaluate the predictive validity of the qSOFA-65, defined as including the age criterion ≥ 65 years to the qSOFA score [33], for the mortality in ICU patients with sepsis, we also used the ROC curves and AUROCs to determine the discriminatory ability of the qSOFA-65 score for deaths in the hospital and ICU. The cut-off value of the qSOFA score was determined by the ROC curve analysis and defined as the cut-off point with the maximum value of Youden's index (i.e., sensitivity + specificity - 1). Based on the cut-off value of the qSOFA score, the patients were classified into two groups. Additionally, based on the cut-off value (≥ 2.0) of the originally-suggested qSOFA score [1, 11], patients were assigned to two groups: either the qSOFA scores of 0 to 1 or the qSOFA scores of 2 to 3.

Upon ICU admission, we assessed factors associated with death in the hospital using logistic regression analysis. To reduce the number of predictors and the multicollinearity issue and resolve the overfitting, we used different ways to select variables as follows: (a) we put all variables of participating hospitals, demographics, and baseline characteristics into the univariable logistic regression model; (b) we selected variables if the P-value was < 0.25 in the univariable logistic regression analysis between survival and death in the hospital, as well as those that are clinically crucial (e.g., sex, age), to put in the multivariable logistic regression model. These variables included participating hospitals (i.e., central hospitals), demographics (i.e., sex, age), documented comorbidities (i.e., cardiovascular disease, chronic neurological disease, solid malignant tumors), sites of infection (i.e., urinary tract, skin, or cutaneous sites), and severity of illness (i.e., qSOFA score). Using a stepwise backward elimination method, we started with the full multivariable logistic regression model that included the selected variables. This method then deleted the variables stepwise from the full model until all remaining variables were independently associated with the risk of death in the hospital in the final model. Similarly, we used these methods of variable selection and analysis for assessing factors associated with death in the ICU. We presented the adjusted odds ratios (AORs) and 95% confidence intervals (CIs) in the multivariable logistic regression model.

For all analyses, significance levels were two-tailed, and we considered $P < 0.05$ as statistically significant. No adjustments for multiple testing were required in this study.

Ethical issues

The Bach Mai Hospital Scientific and Ethics Committees approved this study (approval number: 2919/QD-BM; project code: BM-2017-883-89). We also obtained permission from the heads of institutions and departments of all participating hospitals and their respective institutional review boards wherever available. The study was conducted according to the principles of the Declaration of Helsinki. The Bach Mai Hospital Scientific and Ethics Committees waived written informed consent for this noninterventional study, and public notification of the study was made by public posting. The authors who did the data analysis kept the data sets in password-protected systems and we present anonymized data.

Results

Data on 252 patients with sepsis were submitted to the database of the MOSAICS II study (S1 Fig as shown in [S2 File](#)), in which there were little missing data. Of these patients, 64.3% (162/

252) were men and the median age was 65 years (Q1-Q3: 52–77) (Table 1), of which the median qSOFA score was 2 (Q1-Q3: 1–2) and the median SOFA score was 7 (Q1-Q3: 5–10) at the time of ICU admission. Table 1 also shows that the most common documented comorbidities included cardiovascular disease (31.0%; 78/252), diabetes mellitus (26.6%; 67/252), and chronic neurological disease (14.3%; 36/252) and the most common sites of infection included respiratory (56.7%; 143/252), abdominal cavity (24.2%; 61/252), urinary tract (14.7%; 37/252) and skin or cutaneous sites (7.5%; 19/252). Gram-negative bacteria were isolated in 61.9% (156/252) of patients, with *Acinetobacter baumannii* (17.9%; 45/252) predominating (S1 and S3 Tables as shown in S2 File). Table 2 shows that MV was provided for 68.9% (173/251) of patients and RRT for 40.2% (101/251). Overall, 40.1% (101/252) of patients with sepsis died during the hospital stay, 33.3% (84/252) of whom died in the ICU (Tables 1 and 2). The median ICU and hospital LOS were 10 (Q1-Q3: 6–18) and 16 (Q1-Q3: 10–25) days, respectively (Table 2). The baseline characteristics and life-sustaining treatments during ICU stay were compared between patients who survived and patients who died in the hospital and ICU, as shown in Tables 1 and 2, S1-S4 Tables in S2 File).

In this study, the qSOFA score had a poor discriminatory ability for both the hospital (Fig 1; AUROC: 0.610 [95% CI: 0.538–0.681]; cut-off value: ≥ 2.5 ; sensitivity: 34.7%; specificity: 84.1%; $P_{\text{AUROC}} = 0.003$) and ICU (S2 Fig as shown in S2 File; AUROC: 0.619 [95% CI: 0.544–0.694]; cut-off value: ≥ 2.5 ; sensitivity: 36.9%; specificity: 83.3%; $P_{\text{AUROC}} = 0.002$) mortalities. We also have added the age criterion ≥ 65 years to the qSOFA score and compared this extended score (qSOFA-65) to the original score (qSOFA). However, like the qSOFA score (S3 and S4 Figs as shown in S2 File), the qSOFA-65 also had a poor discriminatory ability for both the hospital (S3 Fig as shown in S2 File; AUROC: 0.548 [95% CI: 0.476–0.619]; cut-off value: ≥ 2.5 ; sensitivity: 53.5%; specificity: 53.0%; $P_{\text{AUROC}} = 0.201$) and ICU (S4 Fig as shown in S2 File; AUROC: 0.562 [95% CI: 0.488–0.636]; cut-off value: ≥ 2.5 ; sensitivity: 56.0%; specificity: 53.6%; $P_{\text{AUROC}} = 0.107$) mortalities.

Based on the cut-off value (≥ 2.5) of the qSOFA score (Fig 1, S2 Fig as shown in S2 File), the patients were classified into two groups, of which the qSOFA score of 3 reflects patients who met all three criteria of the qSOFA score. In the univariable logistic regression analyses, the qSOFA score of 3 was significantly associated with the increased risk of deaths in both the hospital (OR: 2.806; 95% CI: 1.542–5.106) and ICU (OR: 2.925; 95% CI: 1.604–5.333) (Table 3, S5 and S6 Tables as shown in S2 File). Furthermore, the multivariable logistic regression analyses show that the qSOFA score of 3 was independently associated with the increased risk of deaths in both the hospital (AOR: 3.358; 95% CI: 1.756 to 6.422) and ICU (AOR: 3.060; 95% CI: 1.651 to 5.671) (Table 3, S7 and S8 Tables as shown in S2 File). When we replaced the qSOFA score of 3 with the qSOFA score of 2 to 3 in these multivariable logistic regression analyses, we found that the effect size for the qSOFA score of 2 to 3, although, was more modest than those for the qSOFA score of 3, the qSOFA score of 2 to 3 was still an independent predictor of deaths in both the hospital (AOR: 2.101; 95% CI: 1.118 to 3.951) and ICU (AOR: 2.222; 95% CI: 1.153 to 4.282) (S9 and S10 Tables as shown in S2 File).

Discussion

The present study revealed that about a third (33.3%; 84/252) of patients with sepsis died in the ICU, and two-fifths (40.1%; 101/252) died in the hospital. The qSOFA score had a poor discriminatory ability for hospital and ICU mortality. However, a qSOFA score of 3 was independently associated with the increased risk of death in both hospitals and ICUs.

Our figure for the hospital mortality rate was lower than the figures reported previously from LMICs in Southeast Asia, such as Indonesia (68.3%; 41/60) [7], Thailand (42%; 263/627)

Table 1. Demographics and baseline characteristics of intensive care unit patients with sepsis according to hospital survivability.

Variables	All cases	Survived	Died	P-value ^a
	n = 252	n = 151	n = 101	
Participating hospital, no. (%)				0.041
Central hospitals	113 (45.6)	61 (40.4)	54 (53.5)	
Provincial, district, or private hospitals	137 (54.5)	90 (59.6)	47 (46.5)	
Demographics				
Age (year), median (Q1-Q3)	65 (52–77)	65 (53–76)	65 (52–78)	0.810**
Age (year), no. (%)				0.939
< 65	123 (48.8)	74 (49.0)	49 (48.5)	
≥ 65	129 (51.2)	77 (51.0)	52 (51.5)	
Sex (male), no. (%)	162 (64.3)	93 (61.6)	69 (68.3)	0.275
Documented comorbidities				
Cardiovascular disease, no. (%)	78 (31.0)	41 (27.2)	37 (36.6)	0.111
Chronic lung disease, no. (%)	30 (11.9)	18 (11.9)	12 (1.9)	0.992
Chronic neurological disease, no. (%)	36 (14.3)	28 (18.5)	8 (7.9)	0.018
Chronic kidney disease, no. (%)	23 (9.1)	14 (9.3)	9 (8.9)	0.922
Peptic ulcer disease, no. (%)	9 (3.6)	5 (3.3)	4 (4.0)	>0.999*
Chronic liver disease, no. (%)	27 (10.7)	14 (9.3)	13 (12.9)	0.365
Diabetes mellitus, no. (%)	67 (26.6)	40 (26.5)	27 (26.7)	0.966
HIV infection, no. (%)	0 (0.0)	0 (0.0)	0 (0.0)	NA
Connective tissue disease, no. (%)	3 (1.2)	2 (1.3)	1 (1.0)	>0.999*
Immunosuppression, no. (%)	10 (4.0)	7 (4.6)	3 (3.0)	0.744
Hematological malignancies, no. (%)	5 (2.0)	3 (2.0)	2 (2.0)	>0.999*
Solid malignant tumours, no. (%)	12 (4.8)	6 (4.0)	6 (5.9)	0.551*
Vital signs				
GCS, median (Q1-Q3)	13 (9–15)	14 (10–15)	10 (8–14)	<0.001**
HR (beats per min), median (Q1-Q3)	110 (95–126)	110 (92–125)	110 (100–130)	0.083**
Temperature (°C), mean (SD)	37.79 (1.01)	37.80 (1.08)	37.77 (0.91)	0.871**
MBP (mmHg), mean(SD)	75.82 (22.08)	79.75 (22.88)	69.93 (19.51)	0.002**
SBP (mmHg), mean (SD)	106.45 (29.96)	111.39 (29.44)	99.07 (29.35)	0.004**
RR (breaths per min), median (Q1-Q3)	25 (22–30)	25 (22–30)	25 (20–30)	0.693**
Blood investigations				
Total WBC (x10 ⁹ /L), mean (SD)	15.73 (9.20)	15.63 (8.67)	15.88 (9.98)	0.914**
PLT (x10 ⁹ /L), mean (SD)	185.98 (137.85)	200.71 (129.67)	163.95 (147.15)	0.002**
Hb (g/dL), mean (SD)	11.14 (2.59)	11.36 (2.68)	10.82 (2.44)	0.088**
Hct (%), mean (SD)	34.31 (7.75)	35.08 (7.92)	33.17 (7.38)	0.031**
K ⁺ (mmol/L), mean (SD)	3.89 (0.79)	3.90 (0.80)	3.87 (0.77)	0.865**
Na ⁺ (mmol/L), mean (SD)	136.05 (8.24)	135.62 (8.81)	136.69 (7.80)	0.068**
Creatinine (μmol/L), mean (SD)	187.85 (151.92)	186.15 (171.60)	190.38 (117.27)	0.030**
Bilirubin (μmol/l), mean (SD)	32.80 (61.49)	31.74 (72.67)	34.35 (40.09)	0.007**
pH, mean (SD)	7.37 (0.50)	7.41 (0.64)	7.32 (0.14)	0.004**
PaO ₂ (mmHg), mean (SD)	116.17 (74.28)	110.23 (56.25)	124.73 (94.07)	0.665**
PaO ₂ /FiO ₂ ratio, mean (SD)	262.48 (149.58)	281.52 (149.39)	235.26 (146.32)	0.003**
Severity of illness scores				
qSOFA score, median (Q1-Q3)	2 (1–2)	2 (1–2)	2 (2–3)	0.001**
qSOFA score, no. (%)				0.006
0	9 (3.6)	6 (4.0)	3 (3.0)	
1	60 (23.8)	42 (27.8)	18 (17.8)	

(Continued)

Table 1. (Continued)

Variables	All cases	Survived	Died	P-value ^a
	n = 252	n = 151	n = 101	
2	124 (49.2)	79 (52.3)	45 (44.6)	
3	59 (23.4)	24 (15.9)	35 (34.7)	
SOFA score, median (Q1-Q3)	7 (5–10)	6 (4–9)	9 (6–12)	<0.001**
Septic Shock, no. (%)	74 (29.4)	35 (23.2)	39 (38.6)	0.008
Site of Infection				
Respiratory, no. (%)	143 (56.7)	82 (54.3)	61 (60.4)	0.339
Urinary tract, no. (%)	37 (14.7)	30 (19.9)	7 (6.9)	0.004
Abdominal, no. (%)	61 (24.2)	34 (22.5)	27 (26.7)	0.444
Neurological, no. (%)	12 (4.8)	8 (5.3)	4 (4.0)	0.767*
Bones or joints, no. (%)	2 (0.8)	2 (1.3)	0 (0.0)	0.518*
Skin or cutaneous sites, no. (%)	19 (7.5)	7 (4.6)	12 (11.9)	0.033
Intravascular catheter, no. (%)	1 (0.4)	1 (0.7)	0 (0.0)	>0.999*
Infective endocarditis, no. (%)	1 (0.4)	0 (0.0)	1 (1.0)	0.401*
Primary bacteremia, no. (%)	7 (2.8)	5 (3.3)	2 (2.0)	0.705*
Systemic, no. (%)	6 (2.4)	4 (2.6)	2 (2.0)	>0.999*

^aComparison between the patients who survived and died using Chi-squared test

*Fisher's exact test

**Mann-Whitney U test.

Abbreviations

FiO₂: fraction of inspired oxygen; **GCS**: Glasgow coma scale; **Hb**: hemoglobin; **Hct**: hematocrit; **HIV**: human immunodeficiency viruses; **HR**: heart rate; **MBP**: mean arterial blood pressure; **n**, total number of patient; **NA**, not available; **no.**, total number of patients recorded if a variable was given; **PaO₂**: partial pressure of arterial oxygen; **PLT**: platelet; **Q**: quartile; **qSOFA**: quick Sequential (Sepsis-Related) Organ Failure Assessment; **RR**: respiratory rate; **SBP**: systolic blood pressure; **SD**: standard deviation; **SOFA**: Sequential (Sepsis-Related) Organ Failure Assessment; **WBC**: white blood cell.

See (S1 Table as shown in S2 File) for additional information.

<https://doi.org/10.1371/journal.pone.0275739.t001>

[8], and Vietnam (61.0%; 75/123) [9], and lower than the figure reported in the MOSAICS I study (44.5%; 572/1285) [5]. These findings might be due to the definition and management of sepsis having evolved tremendously to improve survival in patients with sepsis and septic shock in the past decade [1, 6, 10, 34–36]. However, our study showed that the ICU and hospital mortality rates were higher than rates reported in the international Extended Study on Prevalence of Infection in Intensive Care (EPIC III) study (28% [99/352] and 31.1% [110/352] in LMICs, 26.4% [821/3114] and 32.7% [1019/3114] in upper-middle-income countries [UMICs], and 21.3% [950/4470] and 28.5% [1275/4470] in high-income countries [HICs]) [37]. These differences might be because the EPIC III study included ICU-acquired infection and not specifically sepsis [37]. Despite the distinct inclusion criteria, our median SOFA score upon admission into the ICU was consistent with those reported in the EPIC III study (7 points [Q1-Q3: 4–11] in LMICs/UMICs/HICs) [37]. However, invasive organ support therapies during ICU stay (i.e., MV and RRT) were more often given to patients in our study than that to patients in the EPIC III study (54.4% [4377/8045] and 15.7% [1253/8045]) [37]. Previous studies showed that MV at any time during the ICU stay was a crucial predictor of death [32, 38]. Additionally, the utilization of RRT at any time during the ICU stay was also associated with increased mortality [32, 38–41]. Furthermore, one of the most dangerous pathogens was *Acinetobacter baumannii*, which was much more commonly isolated from patients in the present study than those in HICs (4.4%; 137/3113) of the EPIC III study [37]. The previous studies showed that *Acinetobacter baumannii* infection was often due to a lack of strict

Table 2. Life-sustaining treatments during intensive care unit (ICU) stay and outcomes of ICU patients with sepsis according to hospital survivability.

Variables	All cases	Survived	Died	P-value ^a
	n = 252	n = 151	n = 101	
Life-sustaining treatments during ICU stay				
Respiratory support, no. (%)				
Mechanical ventilation ^b	173 (68.9)	82 (54.7)	91 (90.1)	<0.001
Non-invasive ventilation ^b	20 (8.0)	13 (8.7)	7 (6.9)	0.618
High-flow nasal oxygen ^b	38 (15.1)	29 (19.3)	9 (8.9)	0.024
Additional ICU support, no. (%)				
Vasopressors/inotropes	163 (64.7)	82 (54.3)	81 (80.2)	<0.001
Renal replacement therapy ^b	101 (40.2)	43 (28.7)	58 (57.4)	<0.001
Red blood cell transfusion ^b	93 (37.1)	48 (32.0)	45 (44.6)	0.043
Platelet transfusion ^b	50 (19.9)	20 (13.3)	30 (29.7)	0.001
Fresh frozen plasma transfusion ^b	58 (23.1)	28 (18.7)	30 (29.7)	0.042
Surgical source control ^b	25 (10.0)	19 (12.7)	6 (5.9)	0.081
Non-surgical source control ^b	78 (31.1)	54 (36.0)	24 (23.8)	0.040
Outcomes				
Patient status, no. (%)				<0.001*
Alive upon current hospital discharge, no. (%)	150 (59.5)	150 (99.3)	0 (0.0)	
Alive upon discharge from current ICU stay, but died in current hospital stay, no. (%)	17 (6.7)	0 (0.0)	17 (16.8)	
Alive upon discharge from current ICU stay, but still in current hospital stay after 90 days, no. (%)	1 (0.4)	1 (0.7)	0 (0.0)	
Still in current ICU stay after 90 days, no. (%)	0 (0.0)	0 (0.0)	0 (0.0)	
Died in current ICU stay, no. (%)	84 (33.3)	0 (0.0)	84 (83.2)	
Length of stay, median days (Q1-Q3)				
Hospital	16 (10–25)	17 (11–24.25)	13 (7–26)	0.027**
ICU	10 (6–18)	10.5 (6–17)	10 (5–21)	0.740**

^aComparison between the patients who survived and died using Chi-squared test

*Fisher's exact test

**Mann-Whitney U test.

^bMissing details from one patient.

Abbreviations

ICU: intensive care unit; n, total number of patient; no., total number of patients recorded if a variable was given; Q: quartile.

See (S2 Table as shown in S2 File) for additional information.

<https://doi.org/10.1371/journal.pone.0275739.t002>

infection control bundles [42] and associated with an increased risk of death [43, 44]. All these findings indicated that the patients, pathogens, and clinical capacity to manage sepsis differ considerably among regions, especially between HIC and LMIC settings, and might explain that our proportions for the ICU and hospital mortality were higher than the rates reported in EPIC III study [37].

In this study, we found a poor ability of the qSOFA score to predict the hospital and ICU mortalities. Despite the first strong predictive validity of the qSOFA score for hospital mortality in patients with suspected infection outside of the ICU [11], there are conflicting data regarding its ability to accurately predict the risk of deaths from sepsis in different populations [12–16]. In an international prospective cohort study of patients presenting to the ED with suspected infection, the predictive validity of qSOFA score for the hospital mortality was acceptable, with an AUROC of 0.800 (95% CI, 0.740 to 0.850), as well as is similar to that of the SOFA score with an AUROC of 0.770 (95% CI, 0.710 to 0.820) [12]. In contrast, another retrospective cohort study shows a poor ability of the qSOFA score for predicting 28-day mortality




Fig 1. The area under the ROC curves of the qSOFA score (AUROC: 0.610 [95% CI: 0.538–0.681]; cut-off value: ≥ 2.5 ; sensitivity: 34.7%; specificity: 84.1%; $P_{\text{AUROC}} = 0.003$) for predicting the hospital mortality in ICU patients with sepsis in Vietnamese ICUs. Abbreviations: AUROC, area under the receiver operating characteristic curve; CI, confidence interval; ICU, intensive care unit; qSOFA, Quick Sequential Organ Failure Assessment; ROC, receiver operating characteristic; SOFA, Quick Sequential Organ Failure Assessment.

<https://doi.org/10.1371/journal.pone.0275739.g001>

in critically ill patients with sepsis on ED arrival, with AUROC of 0.580 (95% CI 0.550 to 0.620) [14]. A large retrospective cohort study also shows the poor discrimination for hospital mortality of the qSOFA score with an AUROC of 0.607 [99% CI, 0.603 to 0.611]) in ICU patients with sepsis [16]. Despite the poor predictive validity of the qSOFA score for the hospital and ICU mortalities among ICU patients with sepsis, our study shows that the predictive validity for hospital mortality of qSOFA score above baseline risk was similar to those of the originally-suggested qSOFA score (AUROC = 0.660; 95% CI, 0.640–0.680; cut-off value: ≥ 2.0) in patients with sepsis in the ICU [1, 11]. Moreover, a recent retrospective population-based cohort study [33] also shows that the poor predictive validity of the qSOFA-65 (AUROC = 0.690; 95% CI, 0.690–0.690) for hospital mortality in patients with community-acquired pneumonia was better than those of the qSOFA-65 for hospital mortality in our ICU patients with sepsis. This difference might be due to a different population between the two studies. The present study shows that the qSOFA score of 3 upon ICU admission was independently associated with the increased risk of death in both the hospital and ICU. Moreover, although the effect size for the qSOFA score of 2 to 3 was more modest than those for the

Table 3. Factors associated with mortality in patients with sepsis upon Vietnamese intensive care unit admission, 2019: Logistic regression analyses.

Factors	Univariable logistic regression analyses ^a				Multivariable logistic regression analyses ^b			
	OR	95% CI for OR		P-value	AOR	95% CI for AOR		P-value
		Lower	Upper			Lower	Upper	
Factors associated with hospital mortality in patients with sepsis								
<i>Participating hospital</i>								
Center hospitals ^c	1.695	1.020	2.819	0.042	1.992	1.110	3.573	0.021
<i>Demographics</i>								
Age of 65 years or older	1.020	0.616	1.688	0.939	NA	NA	NA	NA
Sex (male)	1.345	0.790	2.290	0.275	NA	NA	NA	NA
<i>Documented comorbidities</i>								
Cardiovascular disease	1.551	0.903	2.664	0.112	2.011	1.086	3.721	0.026
Chronic neurological disease	0.378	0.165	0.867	0.022	0.387	0.152	0.983	0.046
Solid malignant tumors	1.526	0.478	4.873	0.475	NA	NA	NA	NA
<i>Site of Infection</i>								
Urinary Tract	0.300	0.126	0.714	0.006	0.270	0.106	0.686	0.006
Skin or Cutaneous Sites	2.774	1.053	7.309	0.039	3.013	1.059	8.571	0.039
<i>Severity of illness score</i>								
qSOFA score of 3	2.806	1.542	5.106	0.001	3.358	1.756	6.422	<0.001
Constant					0.350			<0.001
Factors associated with intensive care unit mortality in patients with sepsis								
<i>Participating hospital</i>								
Central hospitals ^c	1.211	0.716	2.048	0.475	NA	NA	NA	NA
<i>Demographics</i>								
Age of 65 years or older	1.000	0.592	1.689	>0.999	NA	NA	NA	NA
Sex (male)	0.728	0.417	1.272	0.265	NA	NA	NA	NA
<i>Documented comorbidities</i>								
Cardiovascular disease	1.506	0.863	2.627	0.150	NA	NA	NA	NA
Chronic neurological disease	0.526	0.229	1.212	0.131	NA	NA	NA	
Solid malignant tumors	2.077	0.649	6.648	0.218	NA	NA	NA	NA
<i>Site of Infection</i>								
Urinary Tract	0.340	0.136	0.851	0.021	0.318	0.123	0.822	0.018
Skin or cutaneous sites	2.387	0.931	6.123	0.070	2.365	0.893	6.264	0.083
<i>Severity of illness score</i>								
qSOFA score of 3	2.925	1.604	5.333	<0.001	3.060	1.651	5.671	<0.001
Constant					0.400			<0.001

^aEach variable of the hospital and baseline characteristics was analyzed in the univariable logistic regression model and was selected for the multivariate logistic regression model if the P-value was <0.25 between survival and death, as well as those that are clinically crucial.

^bAll selected variables were included in the multivariable logistic regression model with the stepwise backward elimination method. Variables, then, were deleted one by one from the full model until all remaining variables were independently associated with the risk of death in the final model.

^cCenter hospitals included the Thai Nguyen, Bach Mai, Hue, Cho Ray, and Can Tho hospitals. **Abbreviations:** AOR: adjusted odds ratio; CI: confidence interval; NA, not available; OR: odds ratio; qSOFA: quick Sequential (Sepsis-Related) Organ Failure Assessment.

<https://doi.org/10.1371/journal.pone.0275739.t003>

qSOFA score of 3 in our study, the qSOFA score of 2 to 3 was still independently associated with the increased risk of death in both the hospital and ICU. Our findings are consistent with the results of a secondary analysis of 9 data sets from 8 cohort studies in LMICs, of which higher qSOFA scores were associated with a higher risk of death, but predictive validity varied significantly among cohorts which limited the interpretation of the results [45]. Therefore, our

study suggests that despite having a poor discriminatory value, the qSOFA score seems worthwhile in predicting mortality in ICU patients with sepsis in limited-resource settings.

Strengths and limitations

An advantage of the present study was data from the multicenter, which had little missing data (S11 Table as shown in [S2 File](#)). However, the present study has some limitations as follows: (i) *Firstly*, due to the absence of a national registry of ICUs to allow systematic recruitment of units, we used a snowball method to identify suitable units, which might have led to the selection of centers with a greater interest in sepsis management. Therefore, our data are subject to selection bias [46] and might not reflect intensive care throughout Vietnam; (ii) *Secondly*, due to the study's real-world nature, we did not sufficiently protocolize microbiological investigations. Moreover, we mainly evaluated resources utilized in ICUs; therefore, the data detailing the life-sustaining treatments (e.g., fluid balance, administration of steroids, and modalities of RRT and MV) were unavailable; (iii) *Thirdly*, to improve the feasibility of performing the study in busy ICUs, we opted not to collect data on antibiotic resistance and appropriateness; (iv) *Fourthly*, due to our independent variables (e.g., qSOFA) that might be associated with primary outcome (hospital mortality) only measured upon ICU admission, the mixed-effects logistic regression model could not be used to predict discrete outcome variables measured at two different times, i.e., inside and outside the ICU setting. (v) *Finally*, although the sample size was large enough, the confidence interval was slightly wide ($\pm 6.03\%$), which might influence the normal distribution of the sample. Thus, further studies with larger sample sizes might be needed to consolidate the conclusions.

In conclusion, this was a selected cohort of patients with sepsis admitted to the ICUs in Vietnam with high mortality. The qSOFA score had a poor discriminatory ability for mortality; however, the effect size for the qSOFA score of 2 to 3, although, was more modest than those for the qSOFA score of 3, both these score groups were independently associated with the increased risk of deaths in both the hospital and the ICU. Based on the results of our study, despite having a poor discriminatory value, the qSOFA score seems worthwhile in predicting mortality in ICU patients with sepsis in limited-resource settings. However, further studies of the same type are needed by focusing more on the newer simple scoring systems to improve the predictive validity for the outcomes of patients with sepsis.

Supporting information

S1 File.
(PDF)

S2 File.
(PDF)

S1 Dataset.
(XLSX)

Acknowledgments

We thank all ED and ICU staff of participating hospitals for their support with this study. We also thank the staff of the Faculty of Public Health at Thai Binh University of Medicine and Pharmacy for their support and statistical advice. Finally, we thank Miss Phuong Thi Tran from the Center for Emergency Medicine of Bach Mai Hospital, Hanoi, Vietnam, and Miss

Truc-Cam Nguyen from Stanford University, Stanford, California, the United States of America, for their support with this study.

Notes

Son Ngoc Do, Chinh Quoc Luong, My Ha Nguyen, et al. Predictive validity of the quick Sequential Organ Failure Assessment (qSOFA) score for the mortality in patients with sepsis in Vietnamese intensive care units. Abstract presented at European Society of Intensive Care Medicine (ESICM) LIVES 40 Conference; May 12th to 14th, 2022, 2022; Madrid, Spain.

Author Contributions

Conceptualization: Son Ngoc Do, Chinh Quoc Luong.

Data curation: Son Ngoc Do, Chinh Quoc Luong, Nga Thi Nguyen, Dai Quang Huynh, Quoc Trong Ai Hoang, Co Xuan Dao, Thang Dinh Vu, Ha Nhat Bui, Hung Tan Nguyen, Hai Bui Hoang, Thuy Thi Phuong Le, Lien Thi Bao Nguyen, Phuoc Thien Duong, Tuan Dang Nguyen, Vuong Hung Le, Giang Thi Tra Pham.

Formal analysis: Chinh Quoc Luong, My Ha Nguyen, Dung Thi Pham.

Investigation: Son Ngoc Do, Chinh Quoc Luong, My Ha Nguyen, Dung Thi Pham, Nga Thi Nguyen, Dai Quang Huynh, Quoc Trong Ai Hoang, Co Xuan Dao, Thang Dinh Vu, Ha Nhat Bui, Hung Tan Nguyen, Hai Bui Hoang, Thuy Thi Phuong Le, Lien Thi Bao Nguyen, Phuoc Thien Duong, Tuan Dang Nguyen, Vuong Hung Le, Giang Thi Tra Pham, Tam Van Bui, Giang Thi Huong Bui, Jason Phua, Andrew Li, Thao Thi Ngoc Pham, Chi Van Nguyen, Anh Dat Nguyen.

Methodology: Son Ngoc Do, Chinh Quoc Luong, My Ha Nguyen, Dung Thi Pham, Co Xuan Dao, Jason Phua, Andrew Li.

Project administration: Son Ngoc Do, Chinh Quoc Luong.

Supervision: Son Ngoc Do, Chinh Quoc Luong, Co Xuan Dao, Jason Phua, Andrew Li.

Writing – original draft: Chinh Quoc Luong.

Writing – review & editing: Son Ngoc Do, My Ha Nguyen, Dung Thi Pham, Nga Thi Nguyen, Dai Quang Huynh, Quoc Trong Ai Hoang, Co Xuan Dao, Thang Dinh Vu, Ha Nhat Bui, Hung Tan Nguyen, Hai Bui Hoang, Thuy Thi Phuong Le, Lien Thi Bao Nguyen, Phuoc Thien Duong, Tuan Dang Nguyen, Vuong Hung Le, Giang Thi Tra Pham, Tam Van Bui, Giang Thi Huong Bui, Jason Phua, Andrew Li, Thao Thi Ngoc Pham, Chi Van Nguyen, Anh Dat Nguyen.

References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama*. 2016; 315(8):801–10. Epub 2016/02/24. <https://doi.org/10.1001/jama.2016.0287> PMID: 26903338; PubMed Central PMCID: PMC4968574.
2. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *Lancet*. 2020; 395(10219):200–11. Epub 2020/01/20. [https://doi.org/10.1016/S0140-6736\(19\)32989-7](https://doi.org/10.1016/S0140-6736(19)32989-7) PMID: 31954465; PubMed Central PMCID: PMC6970225.
3. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019- results from a systematic review and meta-analysis. *Critical care (London, England)*. 2020; 24(1):239. Epub 2020/05/21. <https://doi.org/10.1186/s13054-020-02950-2> PMID: 32430052; PubMed Central PMCID: PMC7236499.

4. Schultz MJ, Dunser MW, Dondorp AM, Adhikari NK, Iyer S, Kwizera A, et al. Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. *Intensive care medicine*. 2017; 43(5):612–24. Epub 2017/03/30. <https://doi.org/10.1007/s00134-017-4750-z> PMID: 28349179.
5. Phua J, Koh Y, Du B, Tang YQ, Divatia JV, Tan CC, et al. Management of severe sepsis in patients admitted to Asian intensive care units: prospective cohort study. *Bmj*. 2011; 342:d3245. Epub 2011/06/15. <https://doi.org/10.1136/bmj.d3245> PMID: 21669950; PubMed Central PMCID: PMC3113333 www.icmje.org/coi_disclosure.pdf.
6. Li A, Ling L, Qin H, Arabi YM, Myatra SN, Egi M, et al. Epidemiology, Management, and Outcomes of Sepsis in Intensive Care Units Among Countries of Differing National Wealth Across Asia. *American journal of respiratory and critical care medicine*. 2022. Epub June 28, 2022. <https://doi.org/10.1164/rccm.202112-2743OC> PMID: 35763381
7. Dewi RS, Radji M, Andalusia R. Evaluation of Antibiotic Use Among Sepsis Patients in an Intensive Care Unit: A cross-sectional study at a referral hospital in Indonesia. *Sultan Qaboos University medical journal*. 2018; 18(3):e367–e73. Epub 2019/01/05. <https://doi.org/10.18295/squmj.2018.18.03.017> PMID: 30607280; PubMed Central PMCID: PMC6307646.
8. Rudd KE, Hantrakun V, Somayaji R, Booraphun S, Boonsri C, Fitzpatrick AL, et al. Early management of sepsis in medical patients in rural Thailand: a single-center prospective observational study. *Journal of Intensive Care*. 2019; 7(1):55. <https://doi.org/10.1186/s40560-019-0407-z> PMID: 31827803
9. Thao PTN, Tra TT, Son NT, Wada K. Reduction in the IL-6 level at 24 h after admission to the intensive care unit is a survival predictor for Vietnamese patients with sepsis and septic shock: a prospective study. *BMC emergency medicine*. 2018; 18(1):39. Epub 2018/11/08. <https://doi.org/10.1186/s12873-018-0191-4> PMID: 30400775; PubMed Central PMCID: PMC6219151.
10. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Intensive care medicine*. 2003; 29(4):530–8. Epub 2003/03/29. <https://doi.org/10.1007/s00134-003-1662-x> PMID: 12664219.
11. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama*. 2016; 315(8):762–74. Epub 2016/02/24. <https://doi.org/10.1001/jama.2016.0288> PMID: 26903335; PubMed Central PMCID: PMC5433435.
12. Freund Y, Lemachatti N, Krastinova E, Van Laer M, Claessens YE, Avondo A, et al. Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department. *Jama*. 2017; 317(3):301–8. Epub 2017/01/24. <https://doi.org/10.1001/jama.2016.20329> PMID: 28114554.
13. Haydar S, Spanier M, Weems P, Wood S, Strout T. Comparison of QSOFA score and SIRS criteria as screening mechanisms for emergency department sepsis. *The American journal of emergency medicine*. 2017; 35(11):1730–3. Epub 2017/07/18. <https://doi.org/10.1016/j.ajem.2017.07.001> PMID: 28712645.
14. Hwang SY, Jo IJ, Lee SU, Lee TR, Yoon H, Cha WC, et al. Low Accuracy of Positive qSOFA Criteria for Predicting 28-Day Mortality in Critically Ill Septic Patients During the Early Period After Emergency Department Presentation. *Ann Emerg Med*. 2018; 71(1):1–9.e2. Epub 2017/07/04. <https://doi.org/10.1016/j.annemergmed.2017.05.022> PMID: 28669551.
15. Fernando SM, Tran A, Taljaard M, Cheng W, Rochweg B, Seely AJE, et al. Prognostic Accuracy of the Quick Sequential Organ Failure Assessment for Mortality in Patients With Suspected Infection: A Systematic Review and Meta-analysis. *Annals of internal medicine*. 2018; 168(4):266–75. Epub 2018/02/07. <https://doi.org/10.7326/M17-2820> PMID: 29404582.
16. Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit. *Jama*. 2017; 317(3):290–300. Epub 2017/01/24. <https://doi.org/10.1001/jama.2016.20328> PMID: 28114553.
17. World Bank. World Development Indicators Washington, D.C., United States: The World Bank Group; 2019 [updated February 12, 2021; cited 2022 March 19]. Available from: <https://databank.worldbank.org/data/download/POP.pdf>.
18. World Health Organization. Weekly Epidemiological Record, 2003, vol. 78, 35 [full issue]. *Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire*. 2003; 78(35):305–12.
19. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. *Bmj*. 2013; 346:f3039. Epub 2013/06/01. <https://doi.org/10.1136/bmj.f3039> PMID: 23723457; PubMed Central PMCID: PMC3668094 www.icmje.org/coi_disclosure.pdf.

20. World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003–2021, 15 April 2021 Geneva, Switzerland: The World Health Organization; 2021 [updated April 15, 2021; cited 2022 August 31]. Available from: [https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-a\(h5n1\)-reported-to-who-2003-2021-15-april-2021](https://www.who.int/publications/m/item/cumulative-number-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who-2003-2021-15-april-2021).
21. World Health Organization. COVID-19 Situation reports in Viet Nam Geneva, Switzerland: The World Health Organization; 2021 [updated December 15, 2021; cited 2021 December 22]. Available from: [https://www.who.int/vietnam/emergencies/coronavirus-disease-\(covid-19\)-in-viet-nam/covid-19-situation-reports-in-viet-nam/](https://www.who.int/vietnam/emergencies/coronavirus-disease-(covid-19)-in-viet-nam/covid-19-situation-reports-in-viet-nam/).
22. Anders KL, Nguyet NM, Chau NV, Hung NT, Thuy TT, Lien le B, et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. *The American journal of tropical medicine and hygiene*. 2011; 84(1):127–34. Epub 2011/01/08. <https://doi.org/10.4269/ajtmh.2011.10-0476> PMID: 21212214; PubMed Central PMCID: PMC3005500.
23. Mai NT, Hoa NT, Nga TV, Linh le D, Chau TT, Sinh DX, et al. Streptococcus suis meningitis in adults in Vietnam. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2008; 46(5):659–67. Epub 2008/03/01. <https://doi.org/10.1086/527385> PMID: 19413493.
24. Maude RJ, Ngo TD, Tran DT, Nguyen BTH, Dang DV, Tran LK, et al. Risk factors for malaria in high incidence areas of Viet Nam: a case-control study. *Malaria journal*. 2021; 20(1):373. Epub 2021/09/19. <https://doi.org/10.1186/s12936-021-03908-7> PMID: 34535140; PubMed Central PMCID: PMC8446736.
25. Nguyen KV, Thi Do NT, Chandna A, Nguyen TV, Pham CV, Doan PM, et al. Antibiotic use and resistance in emerging economies: a situation analysis for Viet Nam. *BMC public health*. 2013; 13:1158. Epub 2013/12/12. <https://doi.org/10.1186/1471-2458-13-1158> PMID: 24325208; PubMed Central PMCID: PMC4116647.
26. Phu VD, Wertheim HFL, Larsson M, Nadjm B, Dinh Q-D, Nilsson LE, et al. Burden of Hospital Acquired Infections and Antimicrobial Use in Vietnamese Adult Intensive Care Units. *PloS one*. 2016; 11(1):e0147544. <https://doi.org/10.1371/journal.pone.0147544> PMC4732823. PMID: 26824228
27. Dat VQ, Long NT, Giang KB, Diep PB, Giang TH, Diaz JV. Healthcare infrastructure capacity to respond to severe acute respiratory infection (SARI) and sepsis in Vietnam: A low-middle income country. *Journal of critical care*. 2017; 42:109–15. Epub 2017/07/18. <https://doi.org/10.1016/j.jcrc.2017.07.020> PMID: 28711861; PubMed Central PMCID: PMC7126460.
28. Chinh LQ, Manabe T, Son DN, Chi NV, Fujikura Y, Binh NG, et al. Clinical epidemiology and mortality on patients with acute respiratory distress syndrome (ARDS) in Vietnam. *PloS one*. 2019; 14(8):e0221114–e. <https://doi.org/10.1371/journal.pone.0221114> PMID: 31415662; PubMed Central PMCID: PMC31415662.
29. The World Bank. The World Bank In Vietnam. Washington: The World Bank; 2020 [updated October 6, 2020; cited 2022 March 19]. Available from: <https://www.worldbank.org/en/country/vietnam/overview>.
30. Takashima K, Wada K, Tra TT, Smith DR. A review of Vietnam's healthcare reform through the Direction of Healthcare Activities (DOHA). *Environmental health and preventive medicine*. 2017; 22(1):74. Epub 2017/11/23. <https://doi.org/10.1186/s12199-017-0682-z> PMID: 29165160; PubMed Central PMCID: PMC5664805.
31. Asian Critical Care Clinical Trials Group. Management of Sepsis in Asia's Intensive Care unitS II (MOSAICS II) Study Singapore: Society of Intensive Care Medicine (Singapore); 2019 [updated October 2019; cited 2021 December 14]. Available from: <https://sicm.org.sg/article/YDNc8>.
32. Do SN, Luong CQ, Pham DT, Nguyen MH, Nguyen NT, Huynh DQ, et al. Factors relating to mortality in septic patients in Vietnamese intensive care units from a subgroup analysis of MOSAICS II study. *Scientific reports*. 2021; 11(1):18924. Epub 2021/09/25. <https://doi.org/10.1038/s41598-021-98165-8> PMID: 34556710; PubMed Central PMCID: PMC8460806.
33. Kesselmeier M, Pletz MW, Blankenstein AL, Scherag A, Bauer T, Ewig S, et al. Validation of the qSOFA score compared to the CRB-65 score for risk prediction in community-acquired pneumonia. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2021; 27(9):1345.e1–e6. Epub 2020/10/14. <https://doi.org/10.1016/j.cmi.2020.10.008> PMID: 33049414.
34. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. *Intensive care medicine*. 2018; 44(6):925–8. Epub 2018/04/21. <https://doi.org/10.1007/s00134-018-5085-0> PMID: 29675566.
35. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive care medicine*. 2017; 43(3):304–77. Epub 2017/01/20. <https://doi.org/10.1007/s00134-017-4683-6> PMID: 28101605.

36. Phua J, Lim C-M, Faruq MO, Nafees KMK, Du B, Gomersall CD, et al. The story of critical care in Asia: a narrative review. *Journal of Intensive Care*. 2021; 9(1):60. <https://doi.org/10.1186/s40560-021-00574-4> PMID: 34620252
37. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. *Jama*. 2020; 323(15):1478–87. Epub 2020/03/25. <https://doi.org/10.1001/jama.2020.2717> PMID: 32207816; PubMed Central PMCID: PMC7093816.
38. Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Namendys-Silva SA, et al. Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. *Open forum infectious diseases*. 2018; 5(12):ofy313. Epub 2018/12/18. <https://doi.org/10.1093/ofid/ofy313> PMID: 30555852; PubMed Central PMCID: PMC6289022.
39. Sharma S, Kelly YP, Palevsky PM, Waikar SS. Intensity of Renal Replacement Therapy and Duration of Mechanical Ventilation: Secondary Analysis of the Acute Renal Failure Trial Network Study. *Chest*. 2020; 158(4):1473–81. Epub 2020/05/30. <https://doi.org/10.1016/j.chest.2020.05.542> PMID: 32470389.
40. Elseviers MM, Lins RL, Van der Niepen P, Hoste E, Malbrain ML, Damas P, et al. Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury. *Critical care (London, England)*. 2010; 14(6):R221. Epub 2010/12/03. <https://doi.org/10.1186/cc9355> PMID: 21122146; PubMed Central PMCID: PMC3219996.
41. Barbar SD, Clere-Jehl R, Bourredjem A, Hernu R, Montini F, Bruyère R, et al. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. *New England Journal of Medicine*. 2018; 379(15):1431–42. <https://doi.org/10.1056/NEJMoa1803213> PMID: 30304656.
42. Aboshakwa AM, Lalla U, Irusen EM, Koegelenberg CFN. Acinetobacter baumannii infection in a medical intensive care unit: The impact of strict infection control. *African journal of thoracic and critical care medicine*. 2019; 25(1). Epub 2019/04/12. <https://doi.org/10.7196/AJTCCM.2019.v25i1.239> PMID: 34286240; PubMed Central PMCID: PMC8278987.
43. John AO, Paul H, Vijayakumar S, Anandan S, Sudarsan T, Abraham OC, et al. Mortality from acinetobacter infections as compared to other infections among critically ill patients in South India: A prospective cohort study. *Indian journal of medical microbiology*. 2020; 38(1):24–31. Epub 2020/07/29. https://doi.org/10.4103/ijmm.IJMM_19_492 PMID: 32719205.
44. Shargian-Alon L, Gafer-Gvili A, Ben-Zvi H, Wolach O, Yeshurun M, Raanani P, et al. Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies—a retrospective study. *Leukemia & lymphoma*. 2019; 60(11):2787–92. Epub 2019/04/25. <https://doi.org/10.1080/10428194.2019.1599113> PMID: 31014145.
45. Rudd KE, Seymour CW, Aluisio AR, Augustin ME, Bagenda DS, Beane A, et al. Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in Adults With Suspected Infection in Low- and Middle-Income Countries. *Jama*. 2018; 319(21):2202–11. Epub 2018/05/26. <https://doi.org/10.1001/jama.2018.6229> PMID: 29800114; PubMed Central PMCID: PMC6134436.
46. Tripepi G, Jager KJ, Dekker FW, Zoccali C. Selection bias and information bias in clinical research. *Nephron Clinical practice*. 2010; 115(2):c94–9. Epub 2010/04/22. <https://doi.org/10.1159/000312871> PMID: 20407272.